Shenzhen Enduring Biotech | ApexOnco - Clinical Trials news and analysis

x

“Top quality, fast and so easy to use”

Director New Product Planning

Morphosys

Click here for more information

Data insights

8 July 2025

Chia Tai broadens its biparatopic breast cancer approach

The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.

Subscribe to Shenzhen Enduring Biotech